KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Inventory: 2018-2025

Historic Change in Inventory for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $307,000.

  • Castle Biosciences' Change in Inventory rose 121.30% to $307,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 161.64%. This contributed to the annual value of $193,000 for FY2024, which is 95.13% down from last year.
  • Per Castle Biosciences' latest filing, its Change in Inventory stood at $307,000 for Q3 2025, which was down 79.76% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Change in Inventory registered a high of $2.2 million during Q4 2023, and its lowest value of -$1.4 million during Q3 2024.
  • For the 3-year period, Castle Biosciences' Change in Inventory averaged around $426,636, with its median value being $368,000 (2024).
  • In the last 5 years, Castle Biosciences' Change in Inventory soared by 1,991.67% in 2021 and then slumped by 333.00% in 2025.
  • Quarterly analysis of 5 years shows Castle Biosciences' Change in Inventory stood at -$355,000 in 2021, then skyrocketed by 150.14% to $178,000 in 2022, then spiked by 1,120.79% to $2.2 million in 2023, then decreased by 28.07% to $1.6 million in 2024, then spiked by 121.30% to $307,000 in 2025.
  • Its Change in Inventory was $307,000 in Q3 2025, compared to $1.5 million in Q2 2025 and -$1.3 million in Q1 2025.